Paris, November 7, 2016. The Cerba HealthCare Group and METAFORA biosystems are to cooperate in the deployment of METAFORA proprietary technology in the field of metabolomics for diagnostics purposes.

The technological platform developed by METAFORA enables the evaluation of cells’ energy needs in connection with patients’ health. “The investigation into altered metabolic functions for the prevention and detection of disease is a field of major importance, and the availability of new tools such as METAFORA biomarkers is a real asset in the development of new diagnostic tests”, commented Jérôme Sallette, Innovation and Development Director for Cerba HealthCare Group.

The monitoring of normal and altered metabolic functions will provide new knowledge on numerous pathologies, including rare diseases, obesity, diabetes and forms of cancer. It will also enable new tests to be developed to improve the prevention of certain diseases and the maintenance of health through this biological measure. “We are proud to be working with Cerba HealthCare to contribute to the development of diagnostics solutions in the field of metabolism. Thanks to its scientific excellence and the Group’s vast network of laboratories and health professionals, we are confident that this partnership will help us bring our innovative tests to market under the best conditions”, said Vincent Petit, co-founder and CEO of METAFORA biosystems.